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Abstract
Interleukin (IL)-12 has a broad range of activities including regulation of cytokine synthesis and selective promotion of Th1-type cell
development. A shift from a Th1-type response to Th2-type has been suggested to be important in the pathogenesis of dengue hemorrhagic
fever (DHF). This study was undertaken to investigate the possible role of IL-12 in this shift. A total of 76 patients with various grades of
dengue illness and 21 normal healthy controls were tested for IL-12 levels in serum samples and IL-12 mRNA in their peripheral blood
mononuclear cells. The results showed that the levels of IL-12 were the highest in patients with dengue fever (270 þ 102 pg ml31) followed by
decreasing levels in the patients with DHF grade I (198 þ 86 pg ml31 ; P6 0.05) and DHF grade II (84 þ 52 pg ml31 ; P6 0.001). Neither IL-
12 nor its mRNA could be detected in the patients with DHF grades III and IV. The cytokine appeared and reached peak levels during the
first 4 days of illness, started to decline by day 5^8 and disappeared by day 9 onwards. The absence of IL-12 during severe illness and late
phases of the disease may be responsible for the shift to a Th2-type response and thus for the pathogenesis of DHF. ß 2000 Federation of
European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Dengue virus produces either a mild, self-limiting febrile
illness, dengue fever (DF), or a severe, often fatal illness,
dengue hemorrhagic fever (DHF). The characteristic
pathological features of DHF are increased capillary per-
meability, cerebral edema, altered number and functions
of leucocytes, increased hematocrit and thrombocytopenia
[1,2]. Extensive plasma leakage into various serous cavities
of the body may result in profound shock and death.
Despite extensive studies, the pathogenesis of DHF is still
not fully understood. We have recently observed a shift
from a Th1-type cytokine response in DF to a Th2-type
cytokine response in DHF that correlates with increasing
severity of the illness [3]. Dengue virus-infected human
peripheral blood leucocyte cultures also show a similar
cytokine response [4]. This indicated a possible role of
Th1-type cytokines in protection and Th2-type cytokines
in pathogenesis of DHF.
Interleukin (IL)-12, mainly produced by monocytes/
macrophages in response to infectious agents, has a pro-
found e¡ect on the levels of Th1 cells and Th1-type cyto-
kines. The presence of IL-12 upregulates Th1-type cyto-
kines while its absence shifts the balance towards Th2-type
cytokines (reviewed in [5]). Thus, it was possible that high-
er levels of Th1- and Th2-type cytokines in DF and DHF
grades III and IV, respectively, were in response to di¡er-
ences in the levels of IL-12 in these patients. To determine
if such a possibility existed, we have determined the serum
levels of IL-12 and IL-12 mRNA in the peripheral blood
mononuclear cells (PBMC) of patients with DF and DHF.
Our results show that the lack of IL-12 in patients with
DHF grades III and IV may play a role in shifting the
response towards Th2-type cytokines in these patients.
2. Materials and methods
2.1. Patients
Northern India was gripped in an extensive epidemic of
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dengue and DHF during August^November 1996. The
patients su¡ering from typical dengue-like illness admitted
to the Gandhi Memorial and Associated Hospitals, Luck-
now, and the Pediatrics Department of the All India In-
stitute of Medical Sciences, New Delhi, were studied dur-
ing this epidemic. Clinicians examined the patients
thoroughly and laboratory investigations were carried
out. At the time of reporting to the hospital, the clinical
presentation of every patient was recorded, the Hess test
was done and hematocrit values and platelet counts were
measured; the last two tests were repeated daily during the
course of their stay in the hospital. In the present study,
the grade of the illness at the time of admission, when the
blood was collected, has been taken into consideration.
The day of the onset of fever was considered as day 0 of
the illness and thus the day of sample collection was cal-
culated for each patient accordingly. Depending upon the
severity of the illness (clinical presentation) and the ¢nd-
ings of hematocrit and platelet count, they were classi¢ed
as DF or DHF grades I, II, III or IV according to the
criteria of the World Health Organization [6]. A patient
was labeled as of grade I when his hematocrit values were
increased by more than 20%; grade II when he had, in
addition, spontaneous bleeding in skin or other sites ;
grade III had hypotension and/or narrowing of pulse pres-
sure to 20 mm Hg or less, with cold clammy skin and
restlessness (shock); and grade IV had undetectable blood
pressure or pulse (profound shock). A total of 76 patients
were included in the present study. Diagnosis of dengue
virus infection was established either by virus isolation [7]
or by detection of virus-speci¢c IgM in the sera using
standard protocols [8] ; in a number of cases, dengue
IgM capture enzyme-linked immunosorbent assay (ELI-
SA) was also done using commercial kits (Pan BIOS,
East Brisbane, Australia). As controls, 21 normal age-
matched healthy individuals, without history of any febrile
or other illnesses in the previous 3 months, were included.
Among the patients, 16 were classi¢ed as DF, 10 as DHF
grade I, 24 as grade II and 13 each as grade III and grade
IV. Sera collected from the patients (on the ¢rst to the
18th day of illness) and the controls were divided into
aliquots (to avoid repeated freezing and thawing) and
quickly frozen and stored at 360‡C. For the determina-
tion of cytokine concentration, sera were transported to
Kuwait on dry ice and stored at 370‡C until tested.
2.2. Assay of IL-12
Commercial ELISA kits (purchased from RpD Sys-
tems, Minneapolis, MN, USA) were used to measure IL-
12 levels in the sera of patients and controls according to
the instructions of the manufacturer. All the tests were set
up in duplicate and the data were analyzed by Genesis
Windows Software for microplate-based assays (Labsys-
tems, Finland). By this assay, the minimum detectable
concentration of IL-12 was 5 pg ml31. The mean value
of the cytokine in the control sera plus 3 S.D. was used
as ‘cut-o¡’ value for designation of patients sera as pos-
itive or negative. The data were analyzed using Student’s
t test. A P value of less than 0.05 was considered signi¢-
cant. The ¢ndings are presented as mean value þ S.D.
2.3. Preparation of PBMC, mRNA extraction and reverse
transcription (RT-) PCR
PBMC consisting of monocytes and lymphocytes were
separated from the heparinized peripheral venous blood
on Lymphoprep (1.077 g ml31 ; Nyegaard and Co. As.,
Oslo, Norway) as described elsewhere [9,10]. mRNA was
extracted from 10U106 PBMC of the patients and the
controls and used in RT-PCR for human cytokines as
described earlier [11]. Brie£y, mRNA from the PBMC
were extracted by using the Quick Prep Micro mRNA
puri¢cation kit (Pharmacia Biotech, Sweden) according
to the manufacturer’s instructions. cDNA was synthesized
from the mRNA by using a ¢rst strand cDNA synthesis
kit (Pharmacia Biotech, Sweden) according to the protocol
of the kit manufacturer. PCR was performed using the
¢rst strand cDNA as the template and the primers speci¢c
for the cytokine IL-12 (sense 5P-CCCTGACACCTG-
GAGTACTC-3P and antisense 5P-CAGTTAGGTTCTG-
ATCCAGGA-3P). As a positive control, the primers spe-
ci¢c for the house keeping gene, L-actin (sense 5P-
TGACGGGGTCACCCACACTGTGCCCATCTA-3P and
antisense 5P-CTAGAAGCATTGCGGTGGACGATGG-
AGGG-3P), were used. The reagents of the DNA PCR
kit (Perkin-Elmer, Cetus) were used in ampli¢cation reac-
tions according to the manufacturer’s instructions. For
PCR, the cycling parameters were denaturation at 95‡C
for 15 s, annealing at 60‡C for 30 s and extension at
72‡C for 45 s. PCR was performed for 35 cycles followed
by an additional step of extension at 72‡C for 7 min and
the ampli¢ed DNA was analyzed by gel electrophoresis.
The DNA bands for L-actin (661 bp) and IL-12 (227 bp)
were size-identi¢ed by comparing with the bands of mo-
lecular mass marker DNA. In all the specimens, the DNA
corresponding to L-actin was ampli¢ed suggesting that
puri¢ed mRNA was suitable for RT-PCR. Depending
upon the presence or absence of a DNA band of 227 bp
expected size, a specimen was considered positive or neg-
ative for IL-12 mRNA.
3. Results
3.1. Serum levels of IL-12
The mean value of IL-12 in the control sera was
2.6 þ 2.4 pg ml31 with a range of 0^10 pg ml31. The ¢nd-
ings presented in Fig. 1 show that IL-12 was present in the
sera of the patients with DF (70%), DHF grade I (40%)
and DHF grade II (28%), while it was not detectable in
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any of the patients with DHF grade III and DHF grade
IV. As compared to patients with DF (mean value of
270 þ 102 pg ml31), lower levels of IL-12 were detected
in the sera of patients with DHF grade I (198 þ 86;
P6 0.05) and substantially lower levels in patients with
DHF grade II (84 þ 52; P6 0.001). The highest IL-12 val-
ue (670 pg ml31) was seen in one male patient aged 25
years, with DF, on the second day of the illness.
The patients were grouped according to the day of the
illness at the time of collection of the sera, as between days
1 and 4, between days 5 and 8 and day 9 onwards. It was
observed that IL-12 levels were highest during the ¢rst
4 days of illness and the mean values were 265 þ 110 pg
ml31, a lower level (116 þ 60 pg ml31) was found on
days 5^8 and was then not detectable on day 9 onwards
(Fig. 2). The data were further analyzed with respect to
the distribution of the patients with various grades of ill-
ness and the days of illness with detectable IL-12. It was
observed that during the ¢rst 4 days of the illness, the
patients with DF had the highest levels (325 þ 110 pg
ml31) of IL-12 while the patients with DHF grades I
and II had 240 þ 95 pg ml31 and 100 þ 46 pg ml31 of
IL-12, respectively. The number of DHF grade III patients
(n = 2) was too small and no patient of DHF grade IV in
this group was available. During the 5^8 day period, the
levels of IL-12 declined in all the patient groups with a
maximum amount of IL-12 detected in the sera of the
patients with DF (215 þ 93 pg ml31) which were signi¢-
cantly higher (P6 0.001) than the levels in cases with
DHF grade II.
3.2. RT-PCR for IL-12 gene expression
IL-12 gene expression in PBMC of healthy control sub-
jects and in all the 76 patients with dengue was studied by
Fig. 1. Levels of IL-12 in cases of dengue. Sera collected from the pa-
tients with various grades of the illness were screened for IL-12 concen-
tration by sandwich ELISA using commercial kits. The mean values
(line) of the data (pg ml31) and the percentages of the patients positive
for IL-12 (columns) have been presented. The ¢gures in parentheses rep-
resent the total number of the cases in each group.
Fig. 2. Amount of IL-12 in patients sera (pg ml31) as a function of the
stage of dengue illness. The ¢gures in parentheses represent the total
number of patients in each group.
Fig. 3. Ethidium bromide-stained agarose gel of PCR products. Detec-
tion of the IL-12 mRNA (arrow corresponding to 227 bp) ampli¢ed
from the PBMC of the cases of DF (lane 2), DHF grade I (lane 3);
grade II (lane 4); grade III (lane 5); grade IV (lane 6) and; absence of
IL-12 mRNA in the PBMC from a normal healthy control (lane 7); the
mRNA band for L-actin (lane 8) and they were size-identi¢ed by com-
paring with the bands of molecular mass marker DNA (lane 1).
Fig. 4. Comparison of the levels of IL-12 (rectangles) with those of
TGF-L1 (triangles) (see [16]) in the sera of the patients with dengue in
relation to the grades of the illness (A) and the duration of the illness
(B).
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detection of IL-12 mRNA using RT-PCR. The results of
representative experiments with controls, DF and DHF
grade I, II, III and IV patients are given in Fig. 3. The
overall results showed that PBMC from none of the
healthy control subjects and patients with DHF grades
III and IV expressed IL-12 mRNA, whereas 70% of the
patients with DF showed evidence of IL-12 gene expres-
sion in their PBMC.
4. Discussion
IL-12 is primarily produced by monocytes/macrophages
in response to infectious agents (reviewed in [5]). This
cytokine has been associated with protection in a number
of viral infections (reviewed in [5,12]). The results of this
study demonstrate the activation of the IL-12 gene and
elevated levels of IL-12 protein in the patients with milder
dengue illness (DF) and in early time periods. The levels of
IL-12 and mRNA decreased in patients with DHF grades
I and II and disappeared from the patients with DHF
grades III and IV. These ¢ndings suggest that IL-12
is produced early in response to dengue virus infection
and may have a protective role against severe dengue
disease.
IL-12 is an important immunoregulatory cytokine and
has been shown to enhance host cellular responses, includ-
ing the ability to shift the response in favor of Th1-type
and generally promotes clearance of virus and host recov-
ery from infection (reviewed in [12]). Our previous studies
on the same group of dengue patients showed a shift from
the predominant Th1-type cytokine response observed in
66% cases of mild illness (DF) to a Th2-type response in
71% of the patients with severe DHF grade IV which has a
high fatality rate [3]. Studies carried out in the mouse
model support the above ¢ndings (reviewed in [2,3]). On
the basis of these results, it has been proposed that dengue
virus induces the production of a cytokine cascade that
shifts a Th1-dominant response to a Th2-biased response,
resulting in an exacerbation of dengue disease and possibly
death of the patients [2,3]. The results of this study are
consistent with the hypothesis that the presence of IL-12 is
associated with Th1-type response and its absence with the
Th2-type response. Thus IL-12 appears to play a role in
preventing the severe dengue disease by maintaining the
Th1-type response. If this is true, IL-12 therapy may have
a profound bene¢cial e¡ect on the outcome of severe
dengue disease as is seen in a number of other viral in-
fections (reviewed in [12]).
Similar to the ¢ndings of the present study, rapid in-
duction of IL-12 gene expression and production of IL-12
has been reported in a number of viral infections (reviewed
in [5,12]). However, recent studies show that IL-12 is not
essential for the generation of a Th1-type cytokine re-
sponse in mouse hepatitis virus [13] and lymphocytic cho-
riomeningitis virus [14] infections. What factors regulate
Th1 cell di¡erentiation in such situations is not clearly
known.
Macrophages are the principal cells to replicate dengue
virus and present its antigen to immunologically compe-
tent cells (reviewed in [2]), therefore, in dengue virus in-
fection macrophages could be the primary source of IL-12.
Macrophages also produce the cytokine transforming
growth factor-L1 (TGF-L1) which is an important immu-
noregulatory cytokine and has multiple roles to play in the
pathogenesis of viral diseases. TGF-L1 may act as a proin-
£ammatory or anti-in£ammatory cytokine, decreases the
production of free radicals, inhibits receptor expression
and functions of IFN-Q, IL-1K, IL-2 and TNF-K, inhibits
Th1-type cytokines and enhances production of Th2-type
cytokines such as IL-10 (reviewed in [15]). Romani et al.
[5] have suggested that TGF-L is probably the most e¡ec-
tive inhibitor of the IL-12 system, by inhibiting both IL-12
production and its e¡ects on T and NK cells. Our previous
study on the same group of patients has shown that the
levels of TGF-L1 in patients with dengue correlated with
the severity of the disease and the duration of illness, i.e.
the maximum levels of TGF-L1 were detected in patients
with DHF grade IV and those who had the disease for
more than 9 days. In more severely sick patients of DHF
grade III and IV, the levels of TGF-L1 showed a persistent
increase at all time points [16]. The results of serum levels
of TGF-L1 and IL-12, when analyzed together (Fig.
4A,B), show an inverse relationship in patients with DF
and with various grades of DHF and duration of disease.
These ¢ndings warrant an in-depth investigation to deter-
mine the exact role of IL-12 and TGF-L1 in protection
versus pathogenesis of severe dengue disease.
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